1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04602, NCT00424554
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MRC-BR12, EU-20114, ISRCTN83176944, NCT00052455
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0320, NCT00096265
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 021108, NCT00124761
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-22033, EORTC-26033, EudraCT-2004-002714-11, CAN-NCIC-CE5, NCT00182819, TROG 06.01, CE5
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC-05-FB-05235-CTIL, NCT00268684
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0525, EORTC-26052, EORTC-22053, NCT00304031
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: JCOG0504, C000000307, NCT00280475
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04U.534, NCT00328510
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
|
|
11.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MRC-LU24-QUARTZ, EU-20653, ISRCTN3826061, NCT00403065, TROG 07.02
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HYT105962, NCT00390806
|
|
13.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-CE6, EORTC-26062, EORTC-22061, CE6, SPRI-CAN-NCIC-CE.6, NCT00482677
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0398, NCT00500890
|
|
15.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0614, RTOG 0614, NCT00566852
|
|
16.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-26053, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, NCT00626990
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-011, EORTC 26071-22072, NCT00689221
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSAG101-BSA05, NCT00753246
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP 12009-G005, NCT00761280
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00055, NCT00777153
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2301, NCT00789828
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: LEONB-ET2005-006, ET2005-006, LEONB-Nordic Glioma Adulte, INCA-RECF0031, EUDRACT-2006-003606-25, SPRI-LEONB-ET2005-006, NCT00820963
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0825, RTOG 0825, NCT00884741
|
|
24.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0577, N0577, NCT00887146
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0272, N0272, NCT00049127
|
